Overview

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Status:
Not yet recruiting

Trial end date:
2025-04-15

Target enrollment:

Participant gender:

Summary

To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Albumin-Bound Paclitaxel
Docetaxel
Irinotecan
Paclitaxel